Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01729819 · ClinicalTrials.gov registry record · Phase 2
Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT01729819: Completed Phase 2 study, sponsored by Ferring Pharmaceuticals.
NCT01729819 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 106 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01729819, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of nocturnal voids during 3 months of treatment
Primary Outcome
A nocturnal void was defined as a void occurring at least 5 minutes after going to bed, but before getting up the next morning. The mean estimate was the average over 3 consecutive 24-hour periods prior to the respective visit as captured in the voiding and sleep diary.
Interventions
- DRUG Tolterodine tartrate extended release capsules
- DRUG Desmopressin orally disintegrating tablets
- DRUG Placebo orally disintegrating tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
What the finished NCT01729819 record still lists
NCT01729819 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 3 interventions - of which Tolterodine tartrate extended release capsules is the first listed.
NCT01729819 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01729819 about?
NCT01729819 is a clinical study titled "Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women". The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of nocturnal voids during 3 months of treatment
What is the current status of trial NCT01729819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2013-01. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01729819?
The interventions under investigation include: Tolterodine tartrate extended release capsules (DRUG), Desmopressin orally disintegrating tablets (DRUG), Placebo orally disintegrating tablets (DRUG).
Who is sponsoring clinical trial NCT01729819?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01729819's enrollment target sits among peer trials
106 648th of 2000 higher than 1,351 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia